As previously reported, Canaccord downgraded Nevro to Hold from Buy with a price target of $23, down from $30, in conjunction with the firm’s 2024 outlook note on the Biomedical Devices and Services sector. The firm, which notes it had upgraded Nevro in its 2023 kick-off note, says “frankly, we were wrong” as the core SCS market did not recover as expected and PDN continued to ramp, but just not fast enough to offset the weak SCS market. Its recent checks with key opinion leader physicians indicated that the two new private companies entering the U.S. SCS market, Biotronik and Saluda, are likely to take “a disproportionate share” from current Nevro users, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVRO:
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Nevro Announces Acquisition of Vyrsa™ Technologies
- Nevro’s SCS system delivers long-term relief with spinal cord stimulation
- NeuroPace price target raised to $8 from $6 at Morgan Stanley
- Nevro price target lowered to $30 from $57 at Canaccord